Emerging Treatment for ALK-Positive Lung Cancer
The authors discuss emerging treatment options in ALK-positive advanced non-small cell lung cancer and strategies to overcome resistance mechanisms, including newer generation of ALK inhibitors, Hsp90 inhibitors and immunotherapy. [Expert Opin Emerg Drugs] Abstract
Visit our reviews page to see a complete list of reviews in the pulmonary cell research field.
INDUSTRY NEWS
Flatiron Health and the FDA Embark on Cancer Research Collaboration
Flatiron Health and the U.S. Food and Drug Administration (FDA) have signed a research collaboration agreement to determine how real-world evidence derived from de-identified, HIPAA-compliant patient data captured outside of clinical trials can provide new insights into the safety and effectiveness of emerging anti-cancer therapies such as immunotherapeutic agents. [Flatiron Health, Inc.] Press Release